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Abstract
Background:  To determine whether oral administration of geranylgeranylacetone (GGA), a
nontoxic anti-ulcer drug that is an inducer of heat shock protein (HSP) 70, protects against drug-
induced lung injury/fibrosis in vivo.
Methods: We used a bleomycin (BLM)-induced lung fibrosis model in which mice were treated
with oral 600 mg/kg of GGA before and after BLM administration. Inflammation and fibrosis were
evaluated by histological scoring, hydroxyproline content in the lung and inflammatory cell count,
and quantification by ELISA of macrophage inflammatory protein-2 (MIP-2) in bronchoalveolar
lavage fluid. Apoptosis was evaluated by the TUNEL method. The induction of HSP70 in the lung
was examined with western blot analysis and its localization was determined by
immunohistochemistry.
Results: We confirmed the presence of inflammation and fibrosis in the BLM-induced lung injury
model and induction of HSP70 by oral administration of GGA. GGA prevented apoptosis of cellular
constituents of lung tissue, such as epithelial cells, most likely related to the de novo induction of
HSP70 in the lungs. GGA-treated mice also showed less fibrosis of the lungs, associated with the
findings of suppression of both production of MIP-2 and inflammatory cell accumulation in the
injured lung, compared with vehicle-treated mice.
Conclusion: GGA had a protective effect on drug-induced lung injury/fibrosis. Disease-modifying
antirheumatic drugs such as methotrexate, which are indispensable for the treatment of
rheumatoid arthritis, often cause interstitial lung diseases, an adverse event that currently cannot
be prevented. Clinical use of GGA for drug-induced pulmonary fibrosis might be considered in the
future.
Published: 16 September 2009
BMC Pulmonary Medicine 2009, 9:45 doi:10.1186/1471-2466-9-45
Received: 30 December 2008
Accepted: 16 September 2009
This article is available from: http://www.biomedcentral.com/1471-2466/9/45
© 2009 Fujibayashi et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Pulmonary Medicine 2009, 9:45 http://www.biomedcentral.com/1471-2466/9/45
Page 2 of 11
(page number not for citation purposes)
Background
Rheumatoid arthritis (RA), a chronic, systemic, inflamma-
tory autoimmune disease, causes irreversible joint
deformities and functional impairment. Evidence accu-
mulating over the past 10 years has suggested that com-
bined treatment with disease-modifying antirheumatic
drugs (DMARDs), especially methotrexate, and anti-TNFα
biological agents, as early as possible after the diagnosis of
RA is effective and critical for preventing substantial disa-
bility caused by bony erosions [1-4]. On the other hand,
it is also well known that DMARDs and other drugs for RA
have various adverse effects, which require discontinua-
tion or revision of the therapeutic schedule [5,6]. Since
drug-induced interstitial pneumonitis is a well-known
complication among these adverse effects that is often
life-threatening [7-9], investigation for preventing its
onset during the treatment for RA is warranted. Although
the mechanism by which DMARDs cause interstitial
pneumonitis remains unclear, clinical and histopatholog-
ical evaluations suggest that it shares many features with
idiopathic interstitial pneumonitis (IIP) [10,11], allowing
us to speculate that the underlying mechanisms in the
pathogenesis of IIP might be also involved in those in
drug-induced interstitial pneumonia.
Although the pathological roles of cell injury and apopto-
sis in the epithelium of the airways during acute lung
injury and fibrosis have not been fully determined,
increased apoptosis of alveolar epithelial cells (AECs) has
been observed in IIP, not only in the fibrotic lesions, but
also in histologically normal alveoli [12-15].
The heat-shock proteins (HSPs) have a cytoprotective
property as intracellular chaperones, by which aberrantly
folded or mutated proteins involved in various stressful
conditions are repaired and, if necessary, degraded for cel-
lular homeostasis [16,17]. A wide variety of stresses, such
as ischemia and inflammation, induce an increase in the
expression of HSPs, and HSP70 in particular has been
proved to not only exhibit a cytoprotective function
through anti-apoptosis processes against stress in vitro, but
to also exert strong cytoprotection in the stomach, liver,
and heart in vivo [18-21].
Geranylgeranylacetone (GGA), a nontoxic anti-ulcer drug,
has been recently shown to induce HSPs, especially
HSP70, in various animal disease models, which suggests
that the administration of GGA would have a protective
effect against several injury models and human disease
[22-24]. One possible mechanism, by which GGA can
exert the cytoprotection, was shown to be anti-apoptosis
effect by the induction of HSP70 in renal injury model
[25].
To our knowledge, however, the protective effect of GGA
on drug-induced lung injury/fibrosis has not been evalu-
ated, so we investigated whether it had a cytoprotective
effect and inhibited the progression of inflammation and
fibrosis in a bleomycin (BLM)-induced lung fibrosis
model.
Methods
Reagents
Bleomycin was kindly provided by Nippon Kayaku Co.,
Ltd (Tokyo, Japan) and GGA was obtained from Eisai Co.,
Ltd (Tokyo, Japan).
Animals
C57BL/6J (B6) mice (7- to 8-week-old females) purchased
from Chubu Kagaku Shinzai Co., Ltd (Nagoya, Japan)
were randomly divided into treatment groups and given
access to food and water ad libitum. The study was con-
ducted with the approval of Nagoya University Animal
Experimentation and Ethics Committee.
Administration of GGA in naïve mice
GGA was emulsified and prepared in 5% gum arabic and
0.6% Tween 80 for every administration to ensure a fresh
suspension. Naïve mice were given a single oral dose of
GGA at 600 mg/kg or vehicle. At 0, 8, 24 or 48 hours after
the administration of GGA, the mice were exsanguinated
by aortic perforation under pentobarbital sodium
anesthesia. The lung tissues were thoroughly perfused
with saline to remove blood from the vascular bed, as
described before [26], and then samples were collected to
evaluate the induced HSP70 expression.
Some mice were treated with the same dose of GGA at 24
hours after the first administration, and then the lung tis-
sues were collected at 48 hours after the first dose.
Fibrosis model
Acute pulmonary injury and fibrosis was induced by tra-
cheal BLM administration, as described before [27].
Briefly, BLM was suspended in sterile saline and B6 mice
were treated with 2 U/kg of body weight (BW) or the same
volume of sterile saline (BLM mice and saline mice,
respectively). The day of BLM administration was desig-
nated as day 0. To evaluate whether GGA could exert a
protective effect against BLM-induced lung injury and
fibrosis, we monitored BW, the change of which is
assumed to closely correlate with the severity of BLM-
induced lung injury [27].
Administration of GGA in mouse fibrosis model
Mice were pretreated with single daily doses of GGA at
600 mg/kg for 7 days before BLM administration and then
until the indicated time for collection of samples. They
were assigned to 1) vehicle-treated BLM mice, 2) GGA-
treated BLM mice, 3) vehicle-treated saline mice, and 4)
GGA-treated saline mice, respectively.BMC Pulmonary Medicine 2009, 9:45 http://www.biomedcentral.com/1471-2466/9/45
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Collection of tissue specimens
On BLM days 1 and 3, lung tissues were collected from the
treated mice for evaluation of HSP70 expression and
TUNEL staining. On BLM day 7, some mice underwent
bronchoalveolar lavage (BAL) [28]. On BLM day 14, lung
tissues were collected for histological evaluation and
hydroxyproline measurement.
Western blotting analysis for HSP70 expression in vivo
Western blotting analysis was performed with minor
modification [28,29]. Briefly, the resected tissues were
homogenized with six volumes of ice-cold tissue lysis
buffer consisting of 50 mM Tris base-pH 6.8, 2% sodium
dodecyl sulfate (SDS), 150 mM NaCl, 5 mM ethylenedi-
aminetetraacetic acid (EDTA), 1 mM phenylmethylsulfo-
nyl fluoride (PMSF) and Complete, EDTA-free (Roche
Applied Science, Penzberg, Germany). The homogenized
samples were centrifuged twice for 15 minutes at 12,000
× g at 4°C, and aliquots were analyzed for total protein
concentration by the Bradford assay using bovine serum
albumin as the standard. Next, 10% glycerol, 0.005%
bromophenol blue, and 5% β-mercaptoethanol were
added to the supernatants, which were frozen until use.
After correcting for the protein concentration of each sam-
ple of lung tissue, SDS-polysacrylamide electrophoresis
was performed. Protein extracts at a concentration of 40
μg/lane were denatured by heating at 95°C for 4 minutes
and separated on 10% SDS-PAGE gels. Electrophoresis
was performed at 20 mA followed by transfer of proteins
to polyvinylidene difluoride (PVDF) membranes (Milli-
pore Corporation, Billerica, MA, USA). The transferred
membranes were blocked with 5% skim milk in phos-
phate-buffered saline (PBS) solution (0.01 M PBS, pH
7.2) at room temperature for 1 hour and then probed with
the polyclonal rabbit anti-HSP70 antibody (Clone
C92F3A-5, StressGen Biotechnologies Corp., Victoria BC,
Canada) (1:1000), and anti-β-actin antibody (Sigma-
Aldrich, St Louis, MO, USA), diluted in the blocking solu-
tion. Membranes were subsequently rinsed three times in
TBST solution (0.02 M Tris Base-pH 7.5, 0.5 M sodium
chloride, and 0.1% Tween 20) for 10 minutes and
exposed to the secondary HRP-conjugated anti-rabbit IgG
for anti-HSP70 antibody for 1 hour at room temperature.
Bound antibodies were detected with Super Signal®
(Pierce, Rockford, IL, USA). The blots were photographed
with a CCD digital scan camera (Cool Saver, Rise & ATTO
Corporation, Japan). The amount of protein on the
immunoblots was quantified by image software (CS Ana-
lyzer, Rise & ATTO Corporation, Japan), and the expres-
sion levels were presented as ratios to the level of β-actin.
Histological evaluation
On BLM day 14, lung tissue samples from treated mice
were collected and fixed for 24 hours in 10% buffered for-
malin and then embedded in paraffin [30,31]. Sections (4
μm) were stained with hematoxylin-eosin. For the quanti-
tative histological analysis, a numeric scale of fibrosis
(Ashcroft score) was used [32]. Five sections of the entire
lung stained with hematoxylin-eosin were chosen at ran-
dom from each animal and more than 30 successive
microscopic fields at ×100 magnification were allotted a
score from 0 (normal) to 6 (severest) in a blinded fashion.
In each animal the degree of cell infiltration and pneumo-
nitis/fibrosis in the microscopic sections of lung was
assessed as the mean score for the observed fields.
Hydroxyproline analysis
The hydroxyproline content of lung tissue was measured
to evaluate BLM-induced fibrosis, in which excessive col-
lagen deposition is assumed to be one of the most repre-
sentative findings [33]. After the excised lung tissue was
frozen and dried, its dry weight was measured. The tissue
was then hydrolyzed in 6 N HCL (10 mg/mL dry weight)
at 125°C for 18 hours. Using the hydrolysis filtrate as a
hydroxyproline sample, staining was performed with Ehr-
lich's reagent following the Prockop method, and the
quantity of hydroxyproline (μg/mL) in the hydrolysis
products was determined by measuring absorbance at 570
nm with a Shimadzu UV-1200 spectrophotometer.
Immunohistochemical evaluation of HSP70 expression in 
vivo
To evaluate the expression of HSP70 in treated lungs, lung
tissue was fixed in cold 4% paraformaldehyde solution for
6 hours, dehydrated gradually with sucrose over a period
of 24 hours, fixed in OCT compound (Tissue-Tek; Miles,
Elkhart, IN, USA), and frozen. Frozen lung tissue sections
(4 μm) were prepared and incubated with blocking serum
solution in PBS for 1 hour, followed by incubation with
primary rabbit anti-HSP70 antibody (1:1000) at 4°C
overnight. Antigen-antibody complexes were detected by
an avidin-biotin-peroxidase technique (Vectastain ABC
Kit; Vector Laboratories, Burlingame, CA, USA) [34].
Diaminobenzidine (DAB) was used to produce a brown
color in the target tissue, and the sections were perma-
nently mounted.
TUNEL staining for tissue apoptosis in vivo
To assess the degree of lung damage, including apoptosis,
in the early phase, TUNEL staining was performed using
the In Situ Cell Death Detection Kit, POD (Roche Man-
nheim, Germany) and serial sections of the lungs col-
lected on BLM days 1 and 3. The number of TUNEL-
positive cells in the whole area of a mid-sagittal section
was counted under ×400 magnification, and expressed per
total cells.
Bronchoalveolar lavage
To collect BAL fluid, the trachea was cannulated, the lungs
were lavaged six times with PBS (0.5 mL each time) andBMC Pulmonary Medicine 2009, 9:45 http://www.biomedcentral.com/1471-2466/9/45
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approximately 2.5 mL of the instilled fluid was consist-
ently recovered. Total cell numbers were counted with a
standard hemocytometer. Cytospins were prepared by
cytocentrifugation using a Cytospin 2 (Shandon Inc.,
Cheshire, UK) at 1,000 rpm for 5 minutes and then
smears of BAL cells were stained with May-Gruenwald and
Giemsa solutions. Cell differentiation was performed by
counting at least 200 cells using standard hemocytologic
criteria to classify them as alveolar macrophages/mono-
cytes, neutrophils, eosinophils or lymphocytes.
Chemokine assay
The concentration of macrophage inflammatory protein
(MIP)-2 in BAL fluid was determined by ELISA [35]. All
procedures were performed according to the manufac-
turer's instructions.
Statistical analysis
The results were analyzed using the Mann-Whitney test for
comparison between any two groups, and by nonpara-
metric equivalents of ANOVA for multiple comparisons. P
< 0.05 was considered to indicate statistical significance.
Results
GGA-induced HSP70 expression in the lungs in vivo
We confirmed the induction of HSP70 by GGA and eval-
uated the appropriate dose and timing of GGA adminis-
tration  in vivo to induce the maximum expression of
HSP70. In the naïve mice, the level of HSP70 protein in
the lungs of the control vehicle-administered group was
almost the same from 0 to 48 hours, and the level at 24
hours after GGA administration was two-fold greater than
that at 0 hours and in the control vehicle-administered
group (Fig 1A, B). The level of HSP70 protein at 48 hours,
GGA-induced expression of heat shock protein 70 (HSP70) in the lungs Figure 1
GGA-induced expression of heat shock protein 70 (HSP70) in the lungs. (A) Representative immunoblotting data for 
HSP70 and β-actin are shown from two similar and independent experiments. The lung tissues from 5 mice at each time were 
collected. (B) Quantitative results after normalization to the β-actin signal were summarized. Data shown represent the means 
± SE. a; 0 hour, b; 8 hours, c; 24 hours, d; 48 hours, e; 48 hours, repeated administration of geranylgeranylacetone (GGA) at 
24 hours after first administration. *Statistically significant difference (p < 0.05) in comparison with the quantitative value of 
HSP70 level in the lung from mice with vehicle at 0 hours. (C) Representative immunohistochemical staining of HSP70 in GGA-
treated mice at 24 hours after GGA administration. Arrows indicate HSP70-positive cells. (× 400 magnification.)BMC Pulmonary Medicine 2009, 9:45 http://www.biomedcentral.com/1471-2466/9/45
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after further administration of GGA at 24 hours after first
dose, was the same as that at 24 hours (Fig 1A, B: lanes c
and e), whereas the level in the lungs at 48 hours after a
single dose of GGA was decreased by 25% from that at 24
hours (Fig 1A, B: lanes c and d). Furthermore, we evalu-
ated the distribution of GGA-induced HSP70 expression
in the treated lung by immunohistochemical staining.
Immunohistological finding indicated that steady expres-
sion of HSP70 in the lungs from GGA-treated mice
appeared to be located in alveolar septa (Fig 1-C).
Preventive effect of GGA against BLM-induced lung injury 
and fibrosis in vivo Monitoring of BW
The GGA-treated mice did not show any change in BW or
spontaneous movement, compared with the vehicle-
treated mice (Fig 2 and data not shown). GGA-treated
mice with BLM-induced lung injury (GGA-treated BLM
mice) did not show substantial BW loss (1.5% decrease of
BW on BLM day 2) whereas vehicle-treated mice with
BLM-induced lung injury (vehicle-treated BLM mice)
showed significant loss of BW (8.3% decrease on BLM day
7) (Fig 2).
Histological evaluation of the lungs
In comparison with the lungs from vehicle-treated saline
mice (inset in Fig 3A), the lungs of vehicle-treated BLM
mice revealed severe inflammatory cell infiltration in the
subepithelial and subpleural regions with prominent dis-
organized thickening of the alveolar septa, resulting in the
loss of normal structure (Fig 3A). GGA-treated BLM mice
showed a significant decrease in both interstitial infiltra-
tion and airspace cellularity and there were less histologi-
cal changes, compared with vehicle-treated BLM mice (Fig
3B). Quantitative histological scoring of lung injury
showed that the score in the vehicle-treated BLM mice was
significantly higher (3.3 ± 0.5) than that in the GGA-
treated BLM mice (1.7 ± 0.2) (Fig 3C). As the collagen
content of the lung, as measured by hydroxyproline con-
tent, it was also significantly lower in GGA-treated BLM
mice as compared with vehicle-treated BLM mice (vehicle-
treated BLM mice: 72.5 ± 18.8 μg/mL; GGA-treated BLM
mice: 45.3 ± 3.5 μg/mL) (Fig 3D).
Cellular characterization and MIP-2 level in BAL fluid
As previously reported, analysis of the cellular profile in
BAL fluid supports the histological findings [32]. The total
cell number in the BAL fluid increased significantly in
vehicle-treated BLM mice, and was clearly inhibited in
GGA-treated BLM mice (vehicle-treated BLM mice: 110.3
± 15.7 × 104/mL; GGA-treated BLM mice: 39.3 ± 11.1 ×
104/mL) (Fig 4A). GGA treatment significantly suppressed
the number of neutrophils in BAL fluid, as well as alveolar
macrophages/monocytes (neutrophils: 40.5 ± 5.4 × 104/
mL in vehicle-treated BLM mice and 5.2 ± 3.3 × 104/mL in
GGA-treated BLM mice) (Fig 4A). MIP-2 levels in BAL
fluid from GGA-treated BLM mice were significantly sup-
pressed compared with those from vehicle-treated BLM
mice (vehicle-treated BLM mice; 13.0 ± 2.8 pg/mL, GGA-
treated BLM mice; 7.8 ± 1.6/mL, respectively) (Fig 4-B).
Cytoprotective effect of GGA in BLM-induced lung injury 
by TUNEL assay
Until day 3, the histological accumulation of inflamma-
tory cells was still limited and the normal structure of lung
remained (Fig 5C, D), but by day 14 large number of
inflammatory cells had accumulated and the normal
structure was severely damaged in vehicle-treated BLM
mice (Fig 3A). As shown in Fig 5, mainly epithelial cells
were TUNEL-positive, although some cells beneath the
bronchi, most likely inflammatory cells and mesenchy-
mal cells, were also TUNEL-positive. The ratio (%) of
TUNEL-positive cells in the lungs from vehicle-treated
BLM mice on BLM days 1 and 3 was significantly larger
that those from GGA-treated BLM mice at day 1 and day 3
(BLM day 1: 5.0 ± 1.9% in vehicle-treated BLM mice and
2.6 ± 1.5% in GGA-treated BLM mice; BLM day 3: 12.3 ±
3.1% in vehicle-treated BLM mice and 4.7 ± 1.8% in GGA-
treated BLM mice) (Fig 5C, D).
In vivo GGA-induced HSP70 protein expression in BLM-
induced lung injury model
Western blotting analysis showed that the level of HSP70
protein expression in the lungs from GGA-treated BLM
Monitoring of change in body weight (BW) of BLM-treated  mice Figure 2
Monitoring of change in body weight (BW) of BLM-
treated mice. Monitoring of change in body weight (BW) of 
BLM-treated mice at day 0 (GGA-treated mice: n = 5; GGA-
treated BLM mice: n = 10; vehicle-treated BLM mice: n = 10). 
Data represent the mean ± SEM from two independent 
experiments. Comparison of the BW change in each group 
was analyzed using nonparametric equivalents of ANOVA. 
*Statistically significant difference (p < 0.05) in comparison. 
BLM, bleomycin; GGA, geranylgeranylacetone.BMC Pulmonary Medicine 2009, 9:45 http://www.biomedcentral.com/1471-2466/9/45
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mice on BLM day 3 was significantly greater than in vehi-
cle-treated BLM mice at the same time point (vehicle-
treated BLM mice: 1.1 ± 0.1; GGA-treated BLM mice: 1.9 ±
0.2) and that the levels in vehicle-treated saline mice were
the same as those in vehicle-treated BLM mice (Fig 6).
Discussion
We have demonstrated for the first time that repeated oral
administration of GGA exerted a protective effect against
lung injury in a drug-induced lung injury/fibrosis animal
model and subsequently had a suppressive effect on the
fibrotic reaction, related to the induction of HSP70, with-
out remarkable adverse events.
While there is no completely satisfactory animal model of
IIPs and drug-induced interstitial pneumonitis, the intra-
tracheal BLM-induced lung injury model is relatively well-
characterized and does exhibit certain features found in
the human disease. There are clear limitations to this
model in terms of its self-limiting nature, the rapidity of
its development and close association with inflammation
that accompanies the lung injury [26,33]. However, the
model is useful for identification of mechanisms and
pathogenetic clues that may be relevant to the human dis-
ease. Finding such clues may be helpful in providing the
basis for human studies to confirm their relevance.
Histological evaluation and measurement of hydroxyproline Figure 3
Histological evaluation and measurement of hydroxyproline. Histological evaluation in representative H&E stained 
lung sections from vehicle-treated saline mice (Inset in A), vehicle-treated BLM mice (A), and GGA-treated BLM mice (B) on 
BLM day14. All images at × 400 magnification. (C) Quantitative scoring of the severity of histological lung fibrosis (Ashcroft 
score). Data shown represent the mean ± SEM from two independent experiments using 5-10 mice for each group. (D) 
Hydroxyproline assay performed in the lungs from treated mice on BLM day 14. Each group had at least four mice. Data shown 
represent the mean ± SEM from two independent experiments. *Statistically significant difference (p < 0.05) in comparison. 
BLM, bleomycin; GGA, geranylgeranylacetone.BMC Pulmonary Medicine 2009, 9:45 http://www.biomedcentral.com/1471-2466/9/45
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Our finding that BLM-treated mice lost BW, most likely
because of lung injury/fibrosis, was compatible with the
change in BW observed in a previous study [27]. Further-
more, we confirmed in detail that BLM induced the fol-
lowing sequential events as follows: apoptosis,
accumulation of inflammatory cells, increased chemokine
(MIP-2) in BAL fluid, and fibrosis. As it has been accumu-
lated the finding that AECs and endothelial cells injury
and death are a critical finding in both IIPs and BLM-
induced lung fibrosis model [13,36], apoptosis is
assumed to be one of the most important mechanisms, by
which fibrotic reaction was mediated. Lung constituents
such as AECs and endothelial cells are assumed to be sub-
stantial targets in BLM-induced apoptosis in vivo [13,36].
Many studies suggest that AEC injury and apoptosis, con-
sistent findings not only in human IPF/UIP but also in
BLM-induced lung fibrosis model, might induce initial
recruitment of leukocytes, partly because of cytokines and
chemokines released from damaged tissues [13,37-40]. In
particular, MIP-2 could be the most specific chemokine
for the recruitment of neutrophils, by which lung injury
might be amplified and developed [28]. Therefore, it has
been assumed that intra-tracheal administration of BLM
could cause lung injury, partly through the increasing
MIP-2 production in the injured lungs, triggered by AEC
damage/apoptosis [26].
In our present study, the inflammatory process in the
BLM-induced lung injury/fibrosis model was inhibited in
the GGA treated-BLM mice, compared with vehicle
treated-BLM mice, resulting in the attenuation of the
degree of lung fibrosis. These findings were supported by
BAL fluid analyses, including inflammatory cell counts
and quantification of MIP-2 between GGA treated-BLM
mice and vehicle treated-BLM mice. Indeed, the sequen-
tial fibrosis was significantly attenuated, assessed by the
Ashcroft score and the hydroxyproline content of lung tis-
sue. Although the intra-tracheal BLM induced lung fibro-
sis model might not be a completely satisfactory animal
model for drug-induced lung injury/fibrosis, these find-
ings, in which the preventive effect of GGA against BLM-
induced lung fibrosis was successfully shown, could be
the clinically helpful clue in providing the basis on the
therapeutic strategy for drug-induce lung injury/fibrosis.
Cellular profiles and macrophage inflammatory protein-2 (MIP-2) level in bronchoalveolar lavage (BAL) fluid Figure 4
Cellular profiles and macrophage inflammatory protein-2 (MIP-2) level in bronchoalveolar lavage (BAL) fluid. 
(A) Total cell counts and cell differentiation in BAL fluid from treated mice on BLM day 7. At least four mice were prepared for 
each group in each experiment. Data shown represent the mean ± SEM from two independent experiments. TCC: total cell 
counts; Macro/mono: alveolar macrophages/monocytes; Neutro: neutrophils; Eo: eosinophils; Lym: lymphocytes. (B) MIP-2 lev-
els in BAL fluid from treated mice on BLM day 7 was evaluated by ELISA assay. At least four mice were prepared for each 
group in each experiment. Data shown represent the mean ± SEM from two independent experiments. *Statistically significant 
difference (p < 0.05) in comparison.BMC Pulmonary Medicine 2009, 9:45 http://www.biomedcentral.com/1471-2466/9/45
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Importantly, oral treatment with GGA did not cause any
adverse effects and the mice exhibited normal BW gain
and activity during the experiment. GGA treatment signif-
icantly ameliorated BW loss in BLM-treated mice during
the experiment, suggesting that GGA treatment could
exert a general protective effect on damage caused by BLM
administration.
Several reports have suggested that protective effect of
GGA might be, in part, due to inhibit apoptosis process
through induction of HSP70 [25,41-43]. Therefore, we
evaluated the expression of HSP70 in vivo to illuminate
the possible molecular mechanism, by which administra-
tion of GGA could prevent BLM-induced lung injury/
fibrosis in vivo.
Changes in the expression of HSP70 with time after oral
administration of 200 mg/kg of GGA in the rat kidney
[25] and heart [41] have been reported. While one study
reported that induction of HSP70 at 24 hours after a single
oral administration of GGA at 200 mg/kg was not
detected in rat lungs [44], the other report showed the
induction of HSP70 in the rat lungs by intra-arterial
administration of 1000 mg/kg of GGA [45]. To our
knowledge, there has not been a report demonstrating the
induction of HSP70 by oral administration of GGA. In our
Evaluation of cytoprotective effect of GGA against lung injury by in vivo TUNEL assay Figure 5
Evaluation of cytoprotective effect of GGA against lung injury by in vivo TUNEL assay. Evaluation of cytoprotec-
tive effect of GGA against lung injury by in vivo TUNEL assay of the lungs from treated mice on BLM day 1 and day 3. Repre-
sentative lung sections from day3 vehicle-treated BLM mice (A) and GGA-treated BLM mice (B) were shown. TUNEL-positive 
cells (arrows in A and B) were counted in the whole area of the mid-sagittal section (day 1 in C and day 3 in D), expressed 
per total cell counts. At least five mice were prepared for each group in each experiment. Data shown represent the mean ± 
SEM from two independent experiments. *Statistically significant difference (p < 0.05) in comparison. BLM, bleomycin; GGA, 
geranylgeranylacetone.BMC Pulmonary Medicine 2009, 9:45 http://www.biomedcentral.com/1471-2466/9/45
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study, oral administration of GGA at 600 mg/kg clearly
induced increased expression of HSP70 in mouse lungs
beginning at 8 hours and reaching maximal levels by 24
hours, in comparison with the faint expression of HSP70
before treatment with GGA, although HSP70 expression
at 48 hours after a single dose of GGA reverted back to the
same level as at 8 hours. According to these results,
sequential and repeated oral-administration of GGA
before and after the administration of BLM should be
needed to achieve a sufficient protective effect against
BLM-induced lung injury and fibrosis.
To determine whether anti-inflammatory effect by GGA in
vivo may be due to the anti-apoptosis effect by the attribu-
tion of the de novo induction of HSP70 or not, the expres-
sion of HSP70 in the treated lungs were performed by
western blotting. The slight, but not significant increasing
HSP70 expression in the lungs from vehicle treated BLM
mice was observed in our present study, compared with
those from vehicle treated BLM mice. It is suggested in our
present study that the induction of HSP70 by BLM was
limited, although it was reported that BLM induced the
HSP70 promoter in cultured cells [46] and that the mod-
ulation of HSP70 expression by BLM might vary on the
cell types such as fibroblasts and alveolar macrophages
[47,48]. On the other hand, GGA administration induced
the significantly increasing expression of HSP70 in BLM-
treated lungs, compared with that of BLM-treated lung
with vehicle. To evaluate whether GGA treatment can pre-
vent the apoptosis in BLM-treated lungs, TUNEL staining
was performed for the lungs at BLM day1 and day3.
TUNEL staining showed that TUNEL-positive cells were
observed mainly in epithelial cells of BLM-treated lungs at
day1 and day3. The number of TUNEL-positive cells in the
lungs from GGA-treated BLM mice was significantly
smaller than those from vehicle-treated mice with vehicle.
Furthermore, previous study using quercetin, an inhibitor
to the induction of HSPs, showed that quercetin sup-
pressed the expression of HSP70 and abolished the cyto-
protective effect of GGA in renal injury model [25]. Taken
together with the distribution of steady expression of
HSP70 in alveolar septa of the lungs from GGA-treated
mice, our findings allow us to speculate that the in vivo
induction of HSP70 in this model by pretreatment of
GGA might partly protect against BLM-induced cell dam-
age and apoptosis, possibly in AECs, resulting in preven-
tion of sequential inflammation and fibrosis. Although
the up-regulation of HSP70 have been shown in human
tissue injury [24], the HSP70 expression has not yet been
determined in human lung injury. In this study, we
focused on the early effect of GGA on HSP70 induction in
BLM-induced lung injury and fibrosis model in vivo since
it is well assumed that the appropriate control for the ini-
tial triggers on lung injury/fibrosis may result in the atten-
uation of lung injury/fibrosis. Further investigations 1) for
the contribution of GGA on HSP70 induction at later
phase in this model, 2) for the preventive effect of GGA
against the established lung fibrosis, and if so, 3) for
HSP70 protein expression in vivo in BLM-induced lung injury model Figure 6
HSP70 protein expression in vivo in BLM-induced lung injury model. (A) Representative immunoblotting data for 
HSP70 and β-actin on day 3 from two similar and independent experiments. a; vehicle saline mice, b; vehicle BLM mice, c; 
GGA BLM mice. (B) Quantitative results of HSP70 after normalization to β-actin signal were summarized. At least five mice 
were prepared for each group from two independent experiments. Data shown represent the mean ± SEM from two inde-
pendent experiments. *Statistically significant difference (p < 0.05) in comparison. BLM, bleomycin; GGA, geranylgeranylace-
tone; HSP70, heat shock protein 70.BMC Pulmonary Medicine 2009, 9:45 http://www.biomedcentral.com/1471-2466/9/45
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human lung injury, are warranted. Although it is also well
known that both methotrexate and BLM show the cyto-
toxic effect for lung constituents, resulting in apoptosis
[49,50], they are assumed to show different heat shock
responses [47]. It might need to be elucidated by further
study whether GGA might also protect lung injury due to
methotrexate or not.
Conclusion
In conclusion, our present findings are the first to show
that pre-treatment of GGA or GGA-induced derivatives
may give us a new strategy to prevent RA patients from
interstitial pneumonitis induced by DMARDs after due
consideration of both the protocol design in vivo with the
higher experimental dose of GGA than the clinical dose
and the known limitations of BLM-induced fibrosis.
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